summit astrazeneca - Search News

News

AstraZeneca, Lung cancer and Summit Therapeutics

Reuters on MSN · 1d

Summit, AstraZeneca in talks over $15 billion cancer drug licensing deal, Bloomberg News reports

AstraZeneca is in talks with Summit Therapeutics to license an experimental lung-cancer drug under a deal worth as much as $15 billion, Bloomberg News reported on Thursday, citing people familiar with the matter.

The Pharma Letter · 12h

AstraZeneca in talks with Summit for over $15 billion license deal

UK pharma major AstraZeneca is in talks with Summit Therapeutics to license an experimental lung-cancer drug under a deal worth as much as $15 billion, Bloomberg News reported on Thursday, citing people familiar with the matter.

AstraZeneca In $15 Billion Talks For Drug That Could Upend Lung Cancer Treatment

AstraZeneca is in advanced talks with Summit Therapeutics over a potential $15 billion deal for the lung cancer drug ivonescimab.

13h

Summit Therapeutics: AstraZeneca Partnership Could Be A Game-Changer, But Clinical Risks Remain

Summit Therapeutics nears a $15B AstraZeneca deal for ivonescimab, targeting a $90B market. See more on the potential and ...

1don MSN

Why AstraZeneca Stock Got Thumped on Thursday

A cautious market traded AstraZeneca stock down by more than 2% following the report, on a day when the S&P 500 index landed ...

Summit climbs on rumour of $15bn AstraZeneca interest

Shares in Summit Therapeutics have risen sharply on a report that AstraZeneca is in discussions for a partnership focused on ...

7d

4 questions to ask yourself before betting on AI in your business - and why

AI has the potential to democratize information and enhance productivity - but at Snowflake Summit 2025, business leaders ...

1don MSN

Why Summit Therapeutics Stock Soared 8% Higher Today

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Results that may be inaccessible to you are currently showing.

Hide inaccessible results